Interplay between integrins and extracellular matrix is suggested to play an important role in malignant progression and tumor differentiation. The aim of the study was to determine the combined expression of integrin β3 and tenascin-c (TN-c) in breast cancer and examine whether integrin β3 and TN-c can activate urokinase-type plasminogen activator (uPA) through p38 mitogen-activated protein kinase (p38 MAPK). We detected the expression of integrin β3, TN-c, p-p38, and uPA in 80 cases of breast invasive ductal carcinoma by immunohistochemistry. In addition, we blocked integrin β3 and TN-c in the MDA-MB-231 breast cancer cells and detected the expression of p-p38 and uPA by Western blot. Integrin β3, TN-c, p-p38, and uPA showed high levels of expression in breast invasive ductal carcinoma. The expression of integrin β3, TN-c, and uPA was correlated with lymph node metastasis and TNM stage in breast cancer. Furthermore, correlations were noted between any two of the three proteins. The expression of p-p38 and uPA decreased in MDA-MB-231 cells after the addition of integrin β3 antibody and TN-c antibody. The expression of uPA decreased after addition of SB203580. Our results demonstrate that inhibition of the expression of integrin β3 and TN-c could decrease the expression of uPA through p38 MAPK in breast cancer, suggesting that the interaction between integrin β3 and TN-c serves an important role in breast cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0463.2010.02687.xDOI Listing

Publication Analysis

Top Keywords

integrin β3
40
β3 tn-c
28
breast cancer
24
expression integrin
16
p-p38 upa
16
expression upa
12
upa p38
12
p38 mapk
12
integrin
10
expression
10

Similar Publications

Article Synopsis
  • GVHD in the GI tract is a leading cause of death after stem cell transplant, with higher Ann Arbor scores indicating worse outcomes and treatment resistance.
  • A phase 2 study tested natalizumab, a drug that targets T-cells, combined with corticosteroids for patients with severe GVHD, showing that it was safe and well-tolerated.
  • The results revealed no significant benefits of adding natalizumab, as patients had similar recovery and survival rates compared to those who only received corticosteroids.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!